Univariate logistic regression for risk of AM-induced retinopathy. Data represented as N (%) or mean ± SD
| Definite retinopathy | Possible or definite retinopathy | |||||
|---|---|---|---|---|---|---|
| No retinopathy N=668 | Retinopathy N=12 | P | No retinopathy N=652 | Retinopathy N=28 | P | |
| Age | 46.5 ± 15.3 | 43.2 ± 14.3 | 0.452 | 46.4 ± 15.4 | 47.1 ± 12.4 | 0.832 |
| Female | 580 (87%) | 11 (92%) | 0.626 | 567 (87%) | 24 (86%) | 0.848 |
| Weight (kg) | 76.5 ± 19.5 | 67.3 ± 12.8 | 0.098 | 76.5 ± 19.5 | 73.5 ± 17.8 | 0.424 |
| SLE Diagnosis | 271 (41%) | 11 (92%) | 0.008 | 263 (40%) | 19 (68%) | 0.006 |
| AM duration (years) | 9 ± 7.4 | 11.7 ± 5.8 | 0.215 | 8.9 ± 7.3 | 12.8 ± 6.8 | 0.007 |
| AM> 5 years | 417 (63%) | 0 | - | 250 (40%) | 1 (3%) | 0.006 |
| HCQ dose (mg/kg/day) | 5.2 ± 15.5 | 5.9 ± 1.5 | 0.891 | 5.2 ± 15.6 | 5.3 ± 1.4 | 0.971 |
| HCQ total dose (g) | 1042 ± 913.8 | 1235 ± 1032 | 0.471 | 1340 ± 914 | 1187 ± 955 | 0.404 |
| CQ total dose (g) | 46 ± 205.1 | 225± 291 | 0.011 | 37.6 ± 174) | 318 ± 529 | 6.16×10-7 |
| Renal Impairment | 100 (15%) | 2 (17%) | 0.883 | 99 (15%) | 3 (11%) | 0.506 |
| Hypertension | 298 (45%) | 5 (42%) | 0.832 | 285 (44%) | 18 (64%) | 0.038 |
| Diabetes | 61 (9%) | 1 (8%) | 0.924 | 59 (9%) | 3 (11%) | 0.765 |